Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients SIR -Tardive dyskinesia (TD) is a frequent and potentially irreversible extrapyramidal side effect during long-term treatment with typical antipsychotic drugs. Risk factors for the development of TD include age, organic brain damage, psychiatric diagnosis and cumulative dose of neuroleptic medications. Genetic predisposition may also play a role in the etiology of TD. In line with this hypothesis, we have demonstrated an apparent association between homozyosity for the Gly-9 variant (2-2 genotype) of the dopamine D3 receptor (DRD3) and the presence of TD in neuroleptic-treated schizophrenic patients. 1 This finding has recently been supported by other studies, [2] [3] [4] although a non-replication has also recently been published. 5 The DRD3 2-2 genotype may also predispose for drug-induced acute akathisia. 6 It is therefore suggested that inheritance of the Gly-9 DRD3 allele is a genetic susceptibility factor for the development and persistence of dyskinesia.
Still, it is not clear whether the apparent association between the DRD3 genotype and risk for TD is linked to a neuroleptic-induced effect per se, or alternatively, that patients carrying the Gly-9 allele may represent a certain subtype of schizophrenia with a high prevalence of dyskinesia. We have recently observed that dyskinesia may appear with almost the same frequency among never-medicated and antipsychotic-treated schizophrenic patients in India, suggesting that dyskinesia in some cases may be an integral part of the illness, not solely associated with antipsychotic drug treatment. 7 Moreover, orofacial dyskinesia can be observed in a relatively high proportion of drug-naive subjects with schizophrenia or schizophrenia spectrum personality. [8] [9] [10] Based on these data, we decided to investigate whether the apparent DRD3-mediated genetic risk for dyskinetic involuntary movements in schizophrenic patients could be due to the 2-2 genotype per se, as a component of a specific disease phenotype, irrespective of the use of antipsychotic medication. We report our findings in a sample of nevermedicated schizophrenic subjects in India.
Patients were recruited through the non-governmental Schizophrenia Research Foundation (SCARF) in Chennai (formerly Madras), India. We selected and included 62 patients with (n = 31) and without (n = 31) dyskinesia (see below). For each never-medicated subject with dyskinesia included, we recruited one untreated patient without dyskinesia, matched for gender and age (within 5 years). All patients fulfilled DSM-IV criteria for schizophrenia. The diagnosis was based on the history, always obtained from both patient and relative, and mental state assessment, using the Positive and Negative Syndrome Scale. 11 A full medication history was obtained, and we are confident that none of the patients we recruited had previously been exposed to antipsychotic medication. All subjects and their families gave informed consent. Written consent was not possible, as almost all patients were illiterate. The study was approved by the Ethical Review Committee at SCARF, 50% of whose members (medical, legal etc) are not employees of that organisation. Normal controls (n = 22) were recruited from the villages and from SCARF. All patients were examined by one psychiatrist (RGM) for evidence of dyskinesia, using the Abnormal Involuntary Movements Scale (AIMS). 12 Patients were said to have probable dyskinesia if they fulfilled the Schooler and Kane criteria, 13 namely 'mild' movements in at least two areas, or 'moderate' movements in at least one area.
The Ser-9 and Gly-9 variants of the DRD3 receptor gene were identified by a PCR-based MscI restriction enzyme digestion assay, with minor modifications as compared to the method previously described by others. 14 The genotyping was performed blind to the clinical status of the patients. Six of the samples failed to amplify by PCR despite repeated attempts and were therefore excluded from the genetic study and statistical analyses. Exact statistical analyses were performed using StatXact for Windows, version 4.0.1 (Cytel Software Corp, MA, USA). The utility programs of J Ott (ftp://linkage.rockefeller.edu/software/utilities) were used to test for Hardy-Weinberg equilibrium of the genotype distributions.
We genotyped 26 never-treated schizophrenic patients with dyskinesia (14 males and 12 females, with a mean age of 46 years (SD 16 yrs) and a mean length of illness of 14 years (SD 4 yrs)), 30 nevertreated patients without dyskinesia (15 males and 15 females, with a mean age of 45 years (SD 16 yrs) and a mean length of illness of 14 years (SD 5 yrs)) and 22 control subjects (12 males and 10 females, with a mean age of 43 years (SD 15 yrs)). The frequency of allele 1 (Ser9) and allele 2 (Gly9) of the dopamine DRD3 gene and their genotype distributions are shown in Table  1 . The Gly-9 allele had a frequency of 46% (24/52) in patients with dyskinesia, 45% (27/60) in patients without dyskinesia and 48% (21/44) in control samples, demonstrating no significant between-group differences in allele frequency. The distribution of the 1-1, 1-2 and 2-2 genotypes in the total patient sample, in the dyskinesia-negative group and in the control group was in accordance with a Hardy-Weinberg (H-W) equilibrium. In the dyskinesia-positive group, however, the genotype distribution was not in H-W equilibrium ( 2 = 4.01, df = 1, P = 0.045), mainly due to an over-representation of heterozygous subjects.
There were no significant between-group differences together with an over-representation of the 1-2 genotype among the dyskinesia-positive subjects (see above), the overall distribution (2 × 3 table) of the 1-1, 1-2 and 2-2 genotypes was almost significantly different in the dyskinesia-positive vs dyskinesia-negative schizophrenic patients (P = 0.056 by Fisher exact test). Our present data indicate that the Gly-9 variant (allele 2) is more frequent in this Indian population as compared to its frequency in other Asian as well as Caucasian populations. 15 We were not able to demonstrate any association between the Ser9Gly DRD3 genotype and the presence of dyskinesia in drug-naive schizophrenic patients. Due to the low number of subjects, however, with a corresponding insufficient statistical power, the risk of a type 2 (false negative) error is high. Unfortunately, we have not been able to increase the size of our unique sample. The hypothesis that schizophrenic patients homozygous for the Gly-9 allele represent a certain phenotype with a high prevalence of dyskinesia can therefore not be excluded. We anticipate that the inclusion and examination of numerous drug-naive schizophrenic patients with long-lasting illness in general may prove difficult. Still, we would like to challenge other research groups to extend our pilot study, to further examine whether the proposed predisposing role of the Ser9Gly DRD3 polymorphism in dyskinesia development is linked to the use of classical neuroleptic drugs or just appears as an association to a specific schizophrenia phenotype that expresses dyskinesia. A reliable answer, positive or negative, should be highly important. 1 and the association of the DRD4 seven-repeat allele containing genotypes with personality dimensions in alcoholics. 2 Following recent studies showing interaction effects between candidate genes and personality dimensions on the course of substance dependence, [3] [4] [5] we decided to perform a multiple regression analysis to investigate possible interaction effects between novelty seeking and the genotypes containing the seven-repeat allele in the DRD4 and the homozygotes for the ten-repeat allele of the VNTR in the 3Ј untranslated region of the dopamine transporter gene (DAT1).
R
The reason for examining these genes simultaneously is that both have been associated to conditions involving impulsivity or hyperactivity tendencies, especially attention-deficit hyperactivity disorder (ADHD) 6, 7 and novelty seeking, 8 which are relevant to the predisposition to substance abuse. 9 We hypothesized that both genes could interact with nov-
